Receptos, Inc. (f.k.a. Receptor Pharmaceuticals Inc.)

Businessfiled

Receptos, Inc. (f.k.a. Receptor Pharmaceuticals Inc.) operates in Pharmaceuticals, based in SAN DIEGO.

No verified homepage on file yet — operating evidence is limited to the public record.

Capital & rounds (filed)filed

Receptos, Inc. (f.k.a. Receptor Pharmaceuticals Inc.) has raised $30M in disclosed capital across 3 recorded rounds, aggregated from public filings. Its latest round is modeled as Series A (a $4.0M–$15M round).

Largest single filing: $12M on 2009-11-09.

Most recent recorded round closed around 2012-02-03.

Valuation (modeled)modeled

Provath models Receptos, Inc. (f.k.a. Receptor Pharmaceuticals Inc.) at approximately $335M (range $12M–$1.8B). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.

Read: Over-valued. Modeled value is 1.86× the median modeled value of Series A Pharmaceuticals companies in 2010–2012 (57 peers) — value vs value, same stage and era.

Financing rhythm & timingmixed

Historic cadence: a new round about every 16 months.

Last raise 14.4 yr ago; this sector typically re-raises about every 13 months.

Silent for over 3× the sector's normal cadence.

The last round was 1.1× smaller than the prior — a bridge or down round.

Comparablesmixed

Capital scale ranks ahead of 74% of Pharmaceuticals peers (1613 compared).

Modeled value ranks above 76% of those peers.

Closest niche peers: Satori Pharmaceuticals Inc, Labrys Biologics, Inc., Telsar Pharma, Inc., Acetylon Pharmaceuticals, Inc., Seldar Pharma, Inc..

Peoplefiled

16 named people on file across officers, directors and signatories.

Risks & flagsmixed

Financing has been silent well beyond sector cadence — possibly defunct, acquired, or paused.

Modeled above niche peers — valuation risk on entry.

No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.